iPS Cells & Regenerative Medicine Weekly Report May 31, 2026

Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization

Japan: AMCHEPRY® for Parkinson’s (~$350,600) and RiHEART® for Severe Heart Failure (~$63,500+) iPSC Cell Therapies Show Positive Early Clinical Results in 7 Patients

Allogene Therapeutics’ Anti-B7-H3 Allogeneic CAR γδ T Cell Therapy QH104 Shows Favorable Safety, Disease Stabilization in Leptomeningeal Metastasis Phase 1 Trial

Europe’s Biotech Vanguard: Ori Biotech’s Modular Automation Reshapes Cell and Gene Therapy Manufacturing

Genprex’s Reqorsa® Gene Therapy Extends Progression-Free Survival in NSCLC Patients with High Trop-2/Low PTEN Biomarkers, ASCO 2026 Data Shows

CELLINK’s 3D Bioprinting Expands Organoid Production, Accelerating Drug Discovery and Regenerative Medicine

Cynata Therapeutics Anticipates Announcing iPSC-MSC Clinical Results for Knee Osteoarthritis Phase 3 and Acute GvHD Phase 2 Trials Soon

Exosome Therapy Shows Promising Early Clinical Results for Skin Rejuvenation and Hair Loss Treatment, Facing Regulatory Approval Challenges